Literature DB >> 12702557

A promoter that acquired p53 responsiveness during primate evolution.

Ana Contente1, Hans Zischler, Almuth Einspanier, Matthias Dobbelstein.   

Abstract

The tumor suppressor p53 activates the transcription of human PIG3 through direct interaction with a polymorphic microsatellite sequence, (TGYCC)(n). Here, the evolution of this p53-responsive element was recapitulated. Comparison between primate species revealed that the PIG3 promoter acquired this sequence element in its full length only in Hominoidea (apes and humans), whereas the number of TGYCC repeats is far lower in monkeys. Accordingly, only the PIG3 promoters from Hominoidea respond efficiently to p53, whereas those from monkeys respond poorly or not at all. In parallel, the PIG3 gene was strongly induced by p53 in human and chimpanzee cells but was unaffected by p53 in cells derived from a common marmoset monkey. Thus, a novel p53 target gene appeared as recently as during the evolution of primates. This suggests that mechanisms of tumor suppression are subject to ongoing evolution in humans and their closest relatives.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12702557

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Three-dimensional structure and enzymatic function of proapoptotic human p53-inducible quinone oxidoreductase PIG3.

Authors:  Sergio Porté; Eva Valencia; Evgenia A Yakovtseva; Emma Borràs; Naeem Shafqat; Judit E Debreczeny; Ashley C W Pike; Udo Oppermann; Jaume Farrés; Ignacio Fita; Xavier Parés
Journal:  J Biol Chem       Date:  2009-04-05       Impact factor: 5.157

2.  Np9, a cellular protein of retroviral ancestry restricted to human, chimpanzee and gorilla, binds and regulates ubiquitin ligase MDM2.

Authors:  Kristina Heyne; Kathrin Kölsch; Marine Bruand; Elisabeth Kremmer; Friedrich A Grässer; Jens Mayer; Klaus Roemer
Journal:  Cell Cycle       Date:  2015-06-23       Impact factor: 4.534

3.  Of mice and men: fuzzy tandem repeats and divergent p53 transcriptional repertoires.

Authors:  Aurélie Morin; Boris Bardot; Iva Simeonova; Vincent Lejour; Rachida Bouarich-Bourimi; Franck Toledo
Journal:  Transcription       Date:  2013-02-14

4.  Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes.

Authors:  Ulrike Beyer; Julian Moll-Rocek; Ute M Moll; Matthias Dobbelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-07       Impact factor: 11.205

Review 5.  The expanding universe of p53 targets.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

6.  MSK2 inhibits p53 activity in the absence of stress.

Authors:  Susana Llanos; Ana Cuadrado; Manuel Serrano
Journal:  Sci Signal       Date:  2009-09-22       Impact factor: 8.192

7.  Human single-nucleotide polymorphisms alter p53 sequence-specific binding at gene regulatory elements.

Authors:  Omari J Bandele; Xuting Wang; Michelle R Campbell; Gary S Pittman; Douglas A Bell
Journal:  Nucleic Acids Res       Date:  2010-09-03       Impact factor: 16.971

8.  Divergent evolution of human p53 binding sites: cell cycle versus apoptosis.

Authors:  Monica M Horvath; Xuting Wang; Michael A Resnick; Douglas A Bell
Journal:  PLoS Genet       Date:  2007-06-15       Impact factor: 5.917

9.  Reactivation of p53 by a Cytoskeletal Sensor to Control the Balance Between DNA Damage and Tumor Dissemination.

Authors:  Cecilia Herraiz; Fernando Calvo; Pahini Pandya; Gaia Cantelli; Irene Rodriguez-Hernandez; Jose L Orgaz; NaRa Kang; Tinghine Chu; Erik Sahai; Victoria Sanz-Moreno
Journal:  J Natl Cancer Inst       Date:  2015-10-13       Impact factor: 13.506

Review 10.  Detection of a novel, primate-specific 'kill switch' tumor suppression mechanism that may fundamentally control cancer risk in humans: an unexpected twist in the basic biology of TP53.

Authors:  Jonathan W Nyce
Journal:  Endocr Relat Cancer       Date:  2018-06-25       Impact factor: 5.678

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.